发明名称 COMPOUNDS AND METHODS
摘要 This invention relates to substituted benzanilides which are ligands, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease, all in mammals, by the use of substituted benzanilides which are CCR5 receptor antagonists. Furthermore, since CD8+T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor ligands may be useful in the treatment of HIV infection.
申请公布号 WO9901127(A1) 申请公布日期 1999.01.14
申请号 WO1998US13807 申请日期 1998.07.01
申请人 SMITHKLINE BEECHAM CORPORATION;BONDINELL, WILLIAM, E.;CHAN, JAMES, A. 发明人 BONDINELL, WILLIAM, E.;CHAN, JAMES, A.
分类号 C07D295/08;A61K31/138;A61K31/165;A61K31/167;A61K31/245;A61K31/27;A61K31/277;A61K31/40;A61K31/4245;A61K31/438;A61K31/445;A61K31/4453;A61K31/454;A61K31/4741;A61K31/4745;A61K31/4747;A61K31/475;A61K31/535;A61K31/5375;A61K31/55;A61P9/10;A61P11/06;A61P17/00;A61P17/06;A61P29/00;A61P31/18;A61P37/02;A61P37/04;A61P37/08;A61P43/00;C07C233/75;C07C233/80;C07C255/57;C07D207/16;C07D211/14;C07D271/06;C07D295/092;C07D407/12;C07D413/12;C07D491/10;C07D491/20;(IPC1-7):A61K31/41;A61K31/36;A61K31/135 主分类号 C07D295/08
代理机构 代理人
主权项
地址